Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Inhibitor Risk Stratification and Individualized Treatment in Patients With Nonsevere Hemophilia A: A Single-Institution Practice Audit.

Clinical and applied thrombosis/hemostasis : official journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis - 1 Mar 2018

Sun Haowei Linda, Chan Stella, Yenson Paul, Jackson Shannon

Abstract excerpt

Inhibitor risk in nonsevere hemophilia A increases with cumulative factor VIII (FVIII) exposure days and high-risk mutations. A standardized approach to minimize inhibitor risk is warranted. Following establishment of a systematic approach to reduce inhibitor risk in nonsevere hemophilia, we evaluated the uptake of these strategies into clinical practice. All adult males with nonsevere hemophilia A followed by...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Factor VIII
Share to Hemophilia A

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Precision Medicine

Share to Risk Assessment

Share to Young Adult

Source

Open in PubMed Open full text

Identifiers

PMID: 29108420
DOI: 10.1177/1076029617737836
PMCID: PMC6714690

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Inhibitor Risk Stratification and Individualized Treatment in Patients With Nonsevere Hemophilia A: A Single-Institution Practice Audit.PMID 29108420Read ↗

Treatment burden, haemostatic strategies and real world inhibitor screening practice in non-severe haemophilia A.Semantic proximity Read ↗

Acquired hemophilia A: Updated review of evidence and treatment guidance.Semantic proximity Read ↗

The incidence and treatment of bleeding episodes in non-severe haemophilia A patients with inhibitors.Semantic proximity Read ↗

Diagnosis and management of hemophilia A and B.Semantic proximity Read ↗

Inhibitor incidence in an unselected cohort of previously untreated patients with severe haemophilia B: a PedNet studySemantic proximity Read ↗

Prevention of inhibitor development in hemophilia A in 2016. A glimpse into the future?Semantic proximity Read ↗

The Evolution of Hemophilia Care: Clinical and Laboratory Advances, Opportunities, and ChallengesSemantic proximity Read ↗

Assessing risk factors: prevention of inhibitors in haemophilia.Semantic proximity Read ↗

Mutational landscape, inhibitor development, and health-care burden in non-severe haemophilia A: A single-centre Australian experience.Semantic proximity Read ↗

The diagnosis and evaluation of women and girls with hemophilia and hemophilia carriers: guidance from the SSC of the ISTH.Semantic proximity Read ↗

Factor VIII gene (F8) mutation and risk of inhibitor development in nonsevere hemophilia A.Semantic proximity Read ↗

HLA Variants and Inhibitor Development in Hemophilia A: A Retrospective Case-Controlled Study Using the ATHNdatasetSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.